0.2082 -0.002 (-0.86%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 0.25 | 1-year : | 0.29 |
Resists | First : | 0.21 | Second : | 0.25 |
Pivot price | 0.19 ![]() |
|||
Supports | First : | 0.19 | Second : | 0.17 |
MAs | MA(5) : | 0.2 ![]() |
MA(20) : | 0.19 ![]() |
MA(100) : | 0.21 ![]() |
MA(250) : | 1.38 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 76.6 ![]() |
D(3) : | 74.3 ![]() |
RSI | RSI(14): 61.2 ![]() |
|||
52-week | High : | 6.78 | Low : | 0.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LYRA ] has closed below upper band by 0.8%. Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.22 - 0.22 | 0.22 - 0.22 |
Low: | 0.2 - 0.2 | 0.2 - 0.2 |
Close: | 0.21 - 0.21 | 0.21 - 0.21 |
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Tue, 12 Nov 2024
Lyra Therapeutics Inc (LYRA) Q3 2024 Earnings: Net Loss of $11.9M, Misses EPS and Revenue Estimates - GuruFocus.com
Tue, 12 Nov 2024
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Tue, 15 Oct 2024
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Tue, 15 Oct 2024
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - StockTitan
Fri, 27 Sep 2024
Lyra Therapeutics to Present Study Results for LYR-210 and - GlobeNewswire
Wed, 14 Aug 2024
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 65 (M) |
Held by Insiders | 4.171e+007 (%) |
Held by Institutions | 0.6 (%) |
Shares Short | 1,840 (K) |
Shares Short P.Month | 0 (K) |
EPS | -6.704e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -4 % |
Return on Assets (ttm) | 942.5 % |
Return on Equity (ttm) | -42.3 % |
Qtrly Rev. Growth | 1.47e+006 % |
Gross Profit (p.s.) | 1490 |
Sales Per Share | -4796.5 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -1.5 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -78 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.01 |
Price to Cash Flow | -0.03 |
Dividend | 0 |
Forward Dividend | 2.13e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |